Assessing the Use of MY-RIDE, a Just-in-time Adaptive Intervention, to Improve HIV Prevention and Substance Use in Youth Experiencing Homelessness
Part of paid clinical trials in Houston, Texas.
- Sponsor
- The University of Texas Health Science Center, Houston
- Study ID
- NCT06074354
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 25 Years
- Healthy Volunteers
- Not accepted
Interventions
- Attention-control group — BEHAVIORALParticipants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm. They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites. Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
- MY-RIDE group — BEHAVIORALMY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
Study Details
The purpose of this study is to determine whether Motivating Youth to Reduce Infections, Disconnections, and Emotion dysregulation (MY-RIDE) decreases substance use , to determine whether MY-RIDE increases human immunodeficiency virus (HIV) prevention strategies and to evaluate MY-RIDE effects on willingness to take Pre-Exposure Prophylaxis (PrEP), stress, substance use urge, and use of mental health and substance use services when compared to attention control youth
Key Dates
- Start date
- Nov 11, 2024
- Status verified
- May 2026
- Primary completion
- Aug 23, 2027
- Completion
- Aug 23, 2027
Study Design
- Enrollment
- 450 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: MY-RIDE group
- Active Comparator: Attention-control group
Primary Outcome Measure
Change in substance use [ Time Frame: baseline, end of intervention (3 months after baseline), 3 months after intervention, 6 months after intervention, and 12 months after intervention ]
Central Contacts
- Diane M Santa Maria, DrPH, MSN, RN, PHNA-BC, FSAHM713-500-2002
- Jennifer Jones713-500-9928
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas Health Science Center at Houston | Houston | Texas | 77030 |
Find similar trials in Houston, TX
By condition
By specialty
Related Studies
- A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsPHASE1 · Recruiting · ViiV Healthcare · Orlando, Florida
- Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)PHASE2 · Recruiting · Priscilla Hsue, MD · Los Angeles, California
- Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in PediatricsPHASE1/PHASE2 · Recruiting · ViiV Healthcare · Long Beach, California
- First Time in Human Study of Long Acting VH4524184 FormulationsPHASE1 · Recruiting · ViiV Healthcare · Lenexa, Kansas